Estrogen receptor antagonist

Number of patents in Portfolio can not be more than 2000

United States of America

PATENT NO 12221432
APP PUB NO 20220033376A1
SERIAL NO

17309712

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Provided is an indole compound. In particular, disclosed are a compound represented by formula (II) or an isomer or pharmaceutically acceptable salt thereof and a use of the same as an estrogen receptor antagonist in preparing a drug for treating estrogen receptor-positive breast cancer.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD,

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Chen, Shuhui Shanghai, CN 339 290
Ding, Charles Z Shanghai, CN 109 845
Duan, Shuwen Shanghai, CN 2 0
Hu, Guoping Shanghai, CN 62 418
Hu, Lihong Shanghai, CN 71 133
Li, Jian Shanghai, CN 1062 5232
Lu, Jianyu Shanghai, CN 10 9

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Aug 11, 2028
7.5 Year Payment $3600.00 $1800.00 $900.00 Aug 11, 2032
11.5 Year Payment $7400.00 $3700.00 $1850.00 Aug 11, 2036
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00